Prologue: An Evolving Biologics Landscape Driving Innovation and Optimization

Monday, October 17, 2022

8:30 AM – 9:00 AM ET

Location:254 A

Prologue Speaker(s)

Robert Foti, PhD

Senior Director - Bioanalysis, ADME & Discovery Toxicology
Merck

Efforts to identify new therapies have shifted in recent years from a small molecule and antibody dominated focus to a more balanced portfolio that incorporates small molecules, peptides, antibodies and highly engineered proteins designed to evoke complex pharmacological responses. This overview will highlight advancements in bispecific antibodies, fusion proteins and modified endogenous molecules as well as the rapid expansion in the experimental tools available to characterize and optimize these drug candidates.

Learning Objectives:

Descibe recent advancements in protein engineering that have led to the ability to evoke more complex pharmacological responses
Understand key attributes and liabilities associated with newly emerging biologics platforms
Select appropriate experimental assays to characterize the molecular attributes of therapeutic proteins, including those directly influencing PK/PD and efficacy relationships